Company's R&D expenses declined $3.8m
Subscribe to our email newsletter
Ziopharm has reported its financial results for the quarter ended June 30, 2009. The company reported a net loss of $2.4m, or $(0.11) per share, for the second quarter of 2009, as compared to a net loss of $6.5m or $(0.31) per share for the second quarter of 2008.
For the second quarter of 2009, Research and Development expenses declined $3.8m while General and Administrative expenses declined by $0.7m.
The data reveals that the net cash used in operations was $2.2m in the second quarter of 2009, as compared to $6.4m in the same period last year.
Moreover, the decrease in net cash used in operations was primarily attributable to a decrease in net loss from operations of $4.4m. The company ended the June 2009 quarter with cash of approximately $4.5m, which is expected to support operations into the second quarter of 2010.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.